Pharma Marketing Network

New data from the FDA (here) shows that 2014 was a banner year for orphan drugs, which are drugs that treat "rare" diseases/disorders affecting...

There is no more cherished and insulting image of a scientist/researcher than the "mad scientist" persona often depicted in cartoons. A case in point is...

"Welcome to the wild, wild, west of mobile health apps," says the voice over of an IMS Health animated Youtube video (embedded at the...

"Of course I was familiar, from my own practice, with the phenomenon of patients making lists, but I'd never known it had a name,"...

Galderma and PMCPA Tangle in a Toxic Tussle Galderma tried to lay the blame on a rogue Key Account Manager (KAM), but PMCPA would have...

Pharmaceutical companies have a lot of apps in the market, and have been making apps for a long time, but their apps aren’t seeing...

This article is a review of FDA's proposed study titled 'Spousal Influence on Consumer Understanding of and Response to Direct-To-Consumer Prescription Drug Advertisements' (FDA-2014-N-1819)

This article is a review of the proposed FDA 'Experimental Study of Direct-to-Consumer Promotion Directed at Adolescents' (FR # FDA-2013-N-1151), which aims to assess how adolescents interpret drug risk in DTC advertising.

This article reviews the study 'Examination of Online Direct-to-Consumer Prescription Drug Promotion' (FDA-2011-N-0230), which is designed to test different ways of presenting prescription drug risk and benefit information on branded drug Web sites.

Welcome to Volume 13, Issue #10 (DECEMBER 2014) of Pharma Marketing News.